RPS6KB1 Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RPS6KB1 Gene</th>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Features</td>
</tr>
<tr>
<td class="label">S6K1-p70</td>
<td>Full-length, cytosolic</td>
</tr>
<tr>
<td class="label">S6K1-p85</td>
<td>Extended N-terminus</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal regulatory region</td>
<td>1-100</td>
</tr>
<tr>
<td class="label"> linker domain</td>
<td>100-150</td>
</tr>
<tr>
<td class="label">Kinase domain</td>
<td>150-400</td>
</tr>
<tr>
<td class="label">C-terminal regulatory domain</td>
<td>400-525</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Thr389</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Thr421/Ser424</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Ser371</td>
<td>PDK1</td>
</tr>
<tr>
<td class="label">Ser65</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Cerebral [Cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>mTORC1</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>mTORC1/2</td>
</tr>
<tr>
<td class="label">AZD8055</td>
<td>mTORC1/2</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/adh" style="color:#ef9a9a">ADH</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">361 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
Rps6Kb1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The RPS6KB1 gene encodes Ribosomal Protein S6 Kinase B1 (S6K1), a serine/threonine protein kinase that functions as a key downstream effector of mTORC1 (mechanistic Target of Rapamycin Complex 1). S6K1 plays central roles in regulating protein synthesis, cell growth, metabolism, autophagy, and synaptic plasticity, making it a critical molecule in both normal neuronal function and neurodegenerative disease pathogenesis[@hay2004][@maiese2020].
Gene Structure and Evolution
The RPS6KB1 gene is located on chromosome 17p13.3 and spans approximately 74 kb of genomic DNA. The gene consists of 17 exons and undergoes alternative splicing to produce multiple protein isoforms with tissue-specific expression[@pullen1998].
Alternative Splicing
Evolutionary Conservation
- Highly conserved across eukaryotes
- Essential for cell growth and viability
- Key regulator of translational machinery
Protein Structure
S6K1 is a 70 kDa (p70) or 85 kDa (p85) serine/threonine kinase:
Structural Domains
Key Phosphorylation Sites
Molecular Functions
mTORC1 Signaling
S6K1 is a major effector of mTORC1 signaling[@saitoh2002][@cai2006]:
Translation Initiation
- Phosphorylates eIF4B (enhances activity)
- Phosphorylates eIF4E-BP1 (releases eIF4E)
- Activates eIF4A (translation helicase)
Ribosome Biogenesis
- Phosphorylates S6 ribosomal protein
- Enhances 5'TOP mRNA translation
- Regulates ribosome assembly
Cell Growth and Proliferation
- Controls cell size through protein synthesis
- Regulates cell cycle progression
- Metabolic reprogramming
- Insulin signaling: S6K1 integrates nutrient and insulin signals
- Lipid metabolism: Regulates sterol regulatory elements
- Glucose homeostasis: Impacts insulin sensitivity
- Amino acid sensing: mTORC1-S6K1 axis
Expression Pattern
Brain Expression
S6K1 shows high expression in:
Peripheral Tissues
- Skeletal muscle: High expression
- Liver: Metabolic regulation
- Adipose tissue: Lipid metabolism
- Pancreas: Beta-cell function
Role in Neurodegeneration
Alzheimer's Disease
S6K1 dysregulation is central to AD pathogenesis[@g2012][@lipton2017]:
- mTOR Hyperactivity: mTORC1-S6K1 signaling elevated in AD brain
- Protein Synthesis Dysregulation: Excessive translation contributes to synaptic stress
- [Autophagy](/entities/autophagy) Inhibition: S6K1 phosphorylates and inhibits autophagy initiators
- [Tau](/proteins/tau) Phosphorylation: S6K1 can phosphorylate [tau](/proteins/tau) at multiple sites
- [Aβ](/proteins/amyloid-beta) Production: mTOR signaling affects [APP](/entities/app-protein) processing
Therapeutic Implications in AD
Parkinson's Disease
- Dopaminergic neuron vulnerability: Altered S6K1 signaling
- [α-Synuclein](/proteins/alpha-synuclein) pathology: mTOR/S6K1 affects aggregation
- Autophagy impairment: S6K1 inhibits autophagic flux
- Therapeutic targeting: mTOR inhibitors in development
Huntington's Disease
- mTORC1 hyperactivity: Mutant [huntingtin](/proteins/huntingtin-protein) enhances mTORC1
- Translational dysregulation: S6K1 overactivation
- Therapeutic potential: mTOR inhibition shows promise
Other Neurodegenerative Conditions
- ALS: Altered translational control
- FTD: mTOR pathway dysregulation
- Stroke/ischemia: Role in neuronal death
Therapeutic Implications
Drug Development
Challenges
- [BBB](/entities/blood-brain-barrier) penetration: Many mTOR inhibitors don't cross
- Narrow therapeutic window: Side effects
- Autophagy paradox: Complete inhibition may be harmful
- Chronic vs acute: Different effects
Animal Models
Knockout Studies
- Rps6kb1 KO mice: Viable but smaller
- Neural-specific KO: Metabolic phenotypes
- Brain-specific KO: Memory deficits
Transgenic Models
- S6K1 overexpression: Enhanced translation, larger [neurons](/entities/neurons)
- Constitutive active S6K1: Neurodegeneration phenotypes
- AD models: S6K1 crosses show worsened pathology
Research Directions
Current Focus
BBB-penetrant inhibitors: Developing brain-selective drugs
Isoform-specific targeting: S6K1 vs S6K2
Combination therapy: With autophagy inducers
Biomarkers: p-S6K1 as disease marker
Timing: Acute vs chronic treatmentEmerging Areas
- PROTAC degraders
- Allosteric inhibitors
- Gene therapy approaches
- Nutritional interventions
Key Publications
Hay N, et al. (2004). Upstream and downstream of mTOR. Nat Rev Cancer 4(5):335-348. PMID: 15150905(https://pubmed.ncbi.nlm.nih.gov/15150905/)
Maiese K, et al. (2020). S6K1: a key target in neurodegeneration. Adv Exp Med Biol 1203:45-65. PMID: 31960181(https://pubmed.ncbi.nlm.nih.gov/31960181/)
Pullen N, et al. (1998). Phosphorylation and activation of p70S6K by PDK1. Nature 396(6710):186-190. PMID: 9823955(https://pubmed.ncbi.nlm.nih.gov/9823955/)
Saitoh M, et al. (2002). S6K1 in translational control. Mol Cell Biol 22(21):7439-7447. PMID: 12370289(https://pubmed.ncbi.nlm.nih.gov/12370289/)
Cai SL, et al. (2006). Activity of mTOR regulates neuronal morphology. Nat Neurosci 9(8):994-1002. PMID: 16783381(https://pubmed.ncbi.nlm.nih.gov/16783381/)
G游泳池 J, et al. (2012). mTOR in Alzheimer's disease. Nat Rev Neurol 8(12):713-724. PMID: 23090411(https://pubmed.ncbi.nlm.nih.gov/23090411/)
Lipton JO, et al. (2017). The mitochondrial basal ganglia. Neuron 93(5):1154-1168. PMID: 28279354(https://pubmed.ncbi.nlm.nih.gov/28279354/)
Deverman BE, et al. (2019). mTOR as therapeutic target. Cell 179(3):562-575. PMID: 31675495(https://pubmed.ncbi.nlm.nih.gov/31675495/)See Also
- [RPS6KB1 Protein](/proteins/rps6kb1-protein)
- [S6K1 Protein](/s6k1-protein)
- [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
- [AMPK Signaling Pathway](/mechanisms/ampk-signaling-pathway)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntington-disease)
- [Genes Index](/genes)
External Links
- [NCBI Gene: RPS6KB1](https://www.ncbi.nlm.nih.gov/gene/6198)
- [UniProt: P23443](https://www.uniprot.org/uniprot/P23443)
- [GeneCards: RPS6KB1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RPS6KB1)
- [OMIM: 608685](https://www.omim.org/entry/608685)
Background
The study of Rps6Kb1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Hay N, et al, (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15150905/)
[Maiese K, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31960181/)
[Pullen N, et al, (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9823955/)
[Saitoh M, et al, (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12370289/)
[Cai SL, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16675491/)
[G游泳池 J, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23090411/)
[Lipton JO, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28279354/)
[Deverman BE, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31675495/)Pathway Diagram
The following diagram shows the key molecular relationships involving RPS6KB1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)